Flagship startup Serif says it has solved non-viral gene therapy in monkeysnews2026-05-12T10:00:42+00:00May 12th, 2026|Endpoints News|
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2Bnews2026-05-12T09:06:30+00:00May 12th, 2026|Endpoints News|
Optum Rx unveils pharmacy model with clear fees, building on transparency pushnews2026-05-11T20:05:00+00:00May 11th, 2026|Endpoints News|
Rezdiffra is exceeding Wall Street’s expectations as the MASH market takes shapenews2026-05-11T18:27:48+00:00May 11th, 2026|Endpoints News|
Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise pushnews2026-05-11T15:35:21+00:00May 11th, 2026|Endpoints News|
New home for Novo’s Parkinson’s cell therapy; GSK’s deal to sell drug in Chinanews2026-05-11T15:11:26+00:00May 11th, 2026|Endpoints News|
Inhibrx says combo therapy shrank more tumors than Merck’s Keytruda alonenews2026-05-11T14:51:42+00:00May 11th, 2026|Endpoints News|
Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical winnews2026-05-11T13:42:46+00:00May 11th, 2026|Endpoints News|
European regulators greenlight Fractyl Health’s clinical test of GLP-1 gene therapynews2026-05-11T11:00:40+00:00May 11th, 2026|Endpoints News|
CSL sinks to nine-year low on revenue warning, $5B write-downnews2026-05-11T10:30:09+00:00May 11th, 2026|Endpoints News|
